The Additional Hetero Ring Is Six-membered Patents (Class 544/149)
-
Patent number: 11802114Abstract: Disclosed herein are compounds that can be used to selectively detect superoxide in samples. Also disclosed herein are compositions comprising the compounds and methods of detecting superoxide using the compounds.Type: GrantFiled: July 21, 2022Date of Patent: October 31, 2023Assignee: Promega CorporationInventors: Matthew A. Larsen, Hui Wang, Wenhui Zhou, Peter Hofsteen, Jolanta Vidugiriene
-
Patent number: 11433047Abstract: Provided herein are pharmaceutical compositions, each comprising a pyrone compound, for example, a compound of Formula I, and a pharmaceutically acceptable excipient. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of an inflammatory, neurodegenerative, or immune-mediated disease (e.g., multiple sclerosis).Type: GrantFiled: October 7, 2016Date of Patent: September 6, 2022Assignee: NeuroTheryX Canada Ltd.Inventors: Armen Manoukian, Fabrizio Mastronardi, Sam Scanga, Frank Mercurio, Kyle W. H. Chan
-
Publication number: 20150133442Abstract: The invention features compositions and methods for inhibiting the Pin1 protein, and the treatment of disorders characterized by elevated Pin1 levels.Type: ApplicationFiled: June 7, 2013Publication date: May 14, 2015Inventors: Kun Ping Lu, Matthew Brian Boxer, Mindy Irene Emily Davis, Rajan Pragani, Min Shen, Anton Momtchilov Simeonov, Shuo Wei, Xiao Zhen Zhou
-
Publication number: 20140336378Abstract: Disclosed are a novel benzamide derivative and pharmaceutical use thereof, and more particularly, a novel benzamide derivative having a structure of Formula 1 or pharmaceutically acceptable salts thereof, and a composition for prevention or treatment of pain or itching including the above material. The novel benzamide derivative and pharmaceutically acceptable salt thereof according to the present invention exhibit excellent pain-suppressive effect and, in particular, pain-suppressive effect in not only a neuropathic animal model but also other models such as a formalin model, and therefore, may be used in suppression of different pains such as nociceptive pain, chronic pain, etc.Type: ApplicationFiled: November 29, 2012Publication date: November 13, 2014Inventor: Doo Hyun Lee
-
Patent number: 8828678Abstract: A compound comprising the structure: (SIG)-(SI-MOD)m. is provided in which SIG is a signaling molecule, SI is a self-immolative structure bound to SIG such that SIG has a reduced signal relative to the signal of SIG without SI, MOD is a moiety bound to SI that is subject to modification by an activator, and m is an integer from 1 to about 10. When MOD is modified by an activator, SI is destabilized and self-cleaved from SIG such that SIG generates an increased signal. Also provided are methods of determining whether a sample comprises an activator such as a nitroreductase, and methods of determining whether a mammalian cell is hypoxic using a compound of the formula (SIG)-(SI-MOD)m.Type: GrantFiled: November 16, 2010Date of Patent: September 9, 2014Assignee: Enzo Life Sciences, Inc.Inventors: Maciej Szczepanik, Irina V. Lebedeva, Yuejun Xiang, Praveen Pande, Wayne Forrest Patton
-
Publication number: 20140005181Abstract: The present disclosure relates to compounds and methods for treating a disease mediated by apelin.Type: ApplicationFiled: June 20, 2013Publication date: January 2, 2014Applicant: Sanford-Burnham Medical Research InstituteInventors: Layton Smith, Anthony B. Pinkerton
-
Publication number: 20130281366Abstract: The present invention relates to compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation. The present invention is directed towards compounds which can be used to treat diseases such as Hyperlipidemia and also have a beneficial effect on cholesterol.Type: ApplicationFiled: December 26, 2011Publication date: October 24, 2013Applicant: CADILA HEALTHCARE LIMITEDInventors: Harikishore Pingali, Pankaj Makadia, Vrajesh Pankaj, Sairam Kalapatapu, V.V.M., Mukul R. JAIN
-
Publication number: 20120329775Abstract: The present invention provides compounds of formula (I) in which y, m, n, R1, R2 and Q are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.Type: ApplicationFiled: June 4, 2012Publication date: December 27, 2012Inventors: Rhonan Ford, Andrew Mather, Antonio Mete, Ian Millichip
-
Patent number: 8178593Abstract: The invention provides B-sides of urethane formulations, wherein the B-sides comprise both alcohol and epoxy moieties. Also provided are urethane formulations comprising the B-side of the invention, as well as A-sides comprising isocyanate molecules.Type: GrantFiled: February 26, 2010Date of Patent: May 15, 2012Assignee: The Curators of the University of MissouriInventors: Galen Suppes, Fu-Hung Hsieh, Yuan-Chan Tu, Pimphan Kiatsimkul
-
Publication number: 20110201584Abstract: Chemical entities that are bufalin derivatives, pharmaceutical compositions and methods of treatment of cancer are described.Type: ApplicationFiled: January 14, 2011Publication date: August 18, 2011Inventor: Xiangping Qian
-
Publication number: 20100286118Abstract: The present invention provides compounds of formula (I) in which y, m, n, R1, R2 and Q are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.Type: ApplicationFiled: May 6, 2010Publication date: November 11, 2010Inventors: Rhonan Ford, Andrew Mather, Antonio Mete, Ian Millichip
-
Patent number: 7655808Abstract: Leptomycin-type compounds according to formula I wherein R0, R1, R2, R10, R11, R12, R13, R14, and m are as defined herein, exhibit anti-tumor activity.Type: GrantFiled: September 30, 2008Date of Patent: February 2, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Steven D. Dong, Daniel V. Santi, David C. Myles, Brian Hearn
-
Patent number: 7572793Abstract: A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof having inhibitory activity against tau protein kinase 1: wherein R1 represents a C1-C12 alkyl group which may be substituted; R represents, for example, a group represented by the following formula (II): wherein R2 and R3 independently represent a hydrogen atom or a C1-C8 alkyl group; R4 represents a benzene ring which may be substituted, a naphthalene ring which may be substituted, an indan ring which may be substituted, a tetrahydronaphthalene ring which may be substituted, or an optionally substituted heterocyclic ring having 1 to 4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom, and having 5 to 10 ring-constituting atoms in total.Type: GrantFiled: September 20, 2002Date of Patent: August 11, 2009Assignees: Mitsubishi Tanabe Pharma Corporation, Sanofi-AventisInventors: Fumiaki Uehara, Keiichi Aritomo, Aya Shoda, Shinsuke Hiki, Masahiro Okuyama, Yoshihiro Usui, Mitsuru Ooizumi, Kazutoshi Watanabe
-
Publication number: 20090186884Abstract: Described are diaminopropanols of which are orally active and bind to renin to inhibit its activity. They are useful in the treatment or amelioration of diseases associated with elevated levels of renin activity or in the treatment of aspartic protease mediated disorders. Also described is a method for the use of the diaminopropanols in ameliorating or treating renin related disorders in a subject in need thereof.Type: ApplicationFiled: April 5, 2007Publication date: July 23, 2009Inventors: John J. Baldwin, David A. Claremon, Colin M. Tice, Salvacion Cacatian, Lawrence W. Dillard, Alexey V. Ishchenko, Jing Yuan, Zhenrong Xu, Gerard McGeehan, Wei Zhao, Robert D. Simpson, Suresh B. Singh, Patrick T. Flaherty
-
Patent number: 7556751Abstract: Photochromic materials comprising indeno-fused naphthopyrans having a first electron-withdrawing substituent and, in certain non-limiting embodiments, a second electron-withdrawing substituent are disclosed. The photochromic materials according to the various embodiments may display faster fade rates, bathochromic shift, and higher performance ratings compared to comparable indeno-fused naphthopyrans without the electron-withdrawing substituents. Photochromic compositions and articles, such as optical elements, incorporating the photochromic materials are also disclosed.Type: GrantFiled: December 21, 2005Date of Patent: July 7, 2009Assignee: Transitions Optical, Inc.Inventors: Anu Chopra, Beon-Kyu Kim, Barry Van Gemert
-
Patent number: 7527754Abstract: Photochromic materials comprising indeno-fused naphthopyrans having substituents comprising a 4-fluorophenyl group and a 4-aminophenyl group bonded to the 3-position of the indeno-fused naphthopyran are disclosed. The photochromic materials may exhibit faster fade rates as compared to similar indeno-fused naphthopyrans without a 4-fluorophenyl group and a 4-aminophenyl group bonded to the 3-position of the indeno-fused naphthopyran. Substituted 2-propyn-1-ols utilized for the synthesis of the indeno-fused naphthopyrans disclosed herein are disclosed. Photochromic compositions and articles, such as optical elements, incorporating the photochromic materials disclosed herein are also disclosed.Type: GrantFiled: December 21, 2005Date of Patent: May 5, 2009Assignee: Transitions Optical, Inc.Inventor: Anu Chopra
-
Publication number: 20090062533Abstract: Described are naphthols useful in the manufacture of novel indeno-fused photochromic naphthopyran materials.Type: ApplicationFiled: November 11, 2008Publication date: March 5, 2009Applicant: TRANSITIONS OPTICAL, INC.Inventors: Robert W. Walters, Anil Kumar, Clara E. Nelson, Anu Chopra
-
Patent number: 7481955Abstract: Various non-limiting embodiments of the present invention relate to photochromic materials having a metallocenyl group. More particularly, various non-limiting embodiments disclosed herein provide photochromic materials including an indeno-fused naphthopyran, such as an indeno[2?,3?:3,4]naphtho[1,2-b]pyran, and a metallocenyl group bonded to at least one available position on the indeno-fused naphthopyran. Other non-limiting embodiments disclosed herein provide photochromic composition and photochromic articles, such as but not limited to ophthalmic lens, which include the disclosed photochromic materials and method of making the same.Type: GrantFiled: May 31, 2006Date of Patent: January 27, 2009Assignee: Transitions Optical, Inc.Inventor: Wenjing Xiao
-
Patent number: 7446196Abstract: Leptomycin-type compounds according to Formula I wherein R0, R1, R2, R10, R11, R12, R13, R14, and m are as defined herein, exhibit anti-tumor activity.Type: GrantFiled: June 1, 2005Date of Patent: November 4, 2008Assignee: Kosan Biosciences, IncorporatedInventors: Steven Dong, Daniel V. Santi, David C. Myles, Brian Hearn
-
Publication number: 20080234258Abstract: A compound of formula (1) wherein X is H or —OCR1 and Y is H or —OCR2, provided that X and Y are not both H; and R is CH2OR9, CONR11R12, CN, tetrazole or COOR17; or a salt thereof, has therapeutic utility.Type: ApplicationFiled: August 10, 2006Publication date: September 25, 2008Inventors: Andrew Douglas Baxter, Andrea Walmsley
-
Patent number: 7423037Abstract: Compounds of the general formula (I) are inhibitors of the reuptake of norepinephrine. As such, they may be useful for the treatment of disorders of the central and/or peripheral nervous system.Type: GrantFiled: October 28, 2004Date of Patent: September 9, 2008Assignee: Eli Lilly and CompanyInventors: Gordon Iain Campbell, Manuel Javier Cases-Thomas, Teresa Man, John Joseph Masters, Hélène Catherine Eugénie Rudyk, Magnus Wilhelm Walter
-
Patent number: 7312211Abstract: Disclosed are cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (Ia) and (Ib) where R2, R3, R4, R6, R8 and Y are defined herein. The compounds are useful for treating autoimmune and other diseases.Type: GrantFiled: August 26, 2004Date of Patent: December 25, 2007Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Younes Bekkali, Denice Mary Spero, Sanxing Sun, Yancey David Ward
-
Publication number: 20070278461Abstract: Various non-limiting embodiments of the present invention relate to photochromic materials which include a haloalkyl group. More particularly, various non-limiting embodiments disclosed herein provide photochromic materials including an indeno-fused naphthopyran, such as, an indeno[2?,3?:3,4]naphtho[1,2-b] pyran, and a haloalkyl group bonded at the 13-position thereof, wherein the haloalkyl group is a perhalogenated group or a group represented by —O(CH2)a(CX2)bCT3, wherein T is a halogen, each X is independently hydrogen or halogen, a is an integer ranging from 1 to 10, and b is an integer ranging from 1 to 10. Other non-limiting embodiments disclosed herein provide photochromic composition and photochromic articles, such as, but not limited to ophthalmic lens, which include the disclosed photochromic materials and methods of making the same.Type: ApplicationFiled: April 2, 2007Publication date: December 6, 2007Applicant: TRANSITIONS OPTICAL, INC.Inventors: Olga G. Petrovskaia, Anu Chopra, Patrick M. Brown
-
Patent number: 7189714Abstract: Compounds useful for the treatment of pain in accord with the following structural diagram, wherein R1, R2 and R3 are any of a number of groups as defined in the specification and pharmaceutical compositions and methods of treatment utilising such compounds.Type: GrantFiled: October 31, 2001Date of Patent: March 13, 2007Assignee: Astrazeneca ABInventors: Marc Chapdelaine, Lucius Kemp, John McCauley
-
Patent number: 7053212Abstract: The present invention provides estrogen receptor (ER) ligands of structural formula (I) the pharmaceutically acceptable salts, stereoisomers, and prodrugs thereof, and the pharmaceutically acceptable salts of the prodrugs, wherein R1, R2, R3, R4, R5, X, and Q are as defined herein. The invention further provides pharmaceutical compositions comprising the compounds of formula (I), and methods for treating or preventing diseases, disorders, conditions, or symptoms mediated by an ER which comprise administering to a mammalian subject in need of treatment therewith, an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer, or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug, or a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer, or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug.Type: GrantFiled: September 17, 2003Date of Patent: May 30, 2006Assignee: Pfizer Inc.Inventors: Kimberly O. Cameron, Richard Chesworth
-
Patent number: 7026352Abstract: The present invention provides a novel bioactive substance having an antitumor activity and a process for producing it, and a medical use thereof. Namely, it provides a 12-membered ring macrolide compound represented by the following formula obtained from the incubation solution of Streptomyces sp. Mer.Type: GrantFiled: February 1, 2002Date of Patent: April 11, 2006Assignees: Mercian Corporation, Eisai Co., Ltd.Inventors: Yoshiharu Mizui, Takashi Sakai, Satoshi Yamamoto, Keisuke Komeda, Masanori Fujita, Akifumi Okuda, Kumiko Kishi, Jun Niijima, Mitsuo Nagai, Kiyoshi Okamoto, Masao Iwata, Yoshihiko Kotake, Toshimitsu Uenaka, Naoki Asai, Motoko Matsufuji, Tomohiro Sameshima, Naoto Kawamura, Kazuyuki Dobashi, Takashi Nakashima, Masashi Yoshida, Toshio Tsuchida, Susumu Takeda, Tomonari Yamada, Koji Norihisa, Takao Yamori
-
Patent number: 6927217Abstract: The present invention relates to novel dihydropyrones of Formula I wherein X is NH or NR8, which inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for the treatment of viral infections and diseases, including AIDS.Type: GrantFiled: October 16, 2002Date of Patent: August 9, 2005Assignee: Warner-Lambert CompanyInventors: Frederick Earl Boyer, Jr., John Michael Domagala, Edmund Lee Ellsworth, Christopher Andrew Gajda, Elizabeth Ann Lunney, Alexander Pavlovsky, Vara Prasad Venkata Nagendra Josyula, Bradley Dean Tait
-
Patent number: 6833367Abstract: The present invention relates to certain substituted polyketides of formula I, wherein A, B and C are as defined herein, pharmaceutical compositions containing said compounds, and the use of said compounds in treating tumors.Type: GrantFiled: November 12, 2002Date of Patent: December 21, 2004Assignee: Novartis ACInventors: Frederick R. Kinder, Jr., Kenneth W. Bair, Timothy M. Ramsey, Michael L. Sabio
-
Publication number: 20040254184Abstract: The present invention relates compounds of the formula (I); wherein R1, R2, R3, R4, R5, R6, R7, R8, and R10 represent a variety of substituents; A represents NR9 or O; B represents a bond, CH2, NR9 or O, wherein one or both hydrogen atoms in said CH2 moiety may be replaced with one or both of R7 and R8, or alternatively, one of the hydrogen atoms in said CH2 moiety together with a hydrogen atom from an adjacent carbon are replaced by a double bond; with the proviso that when A is O, then B is NR9; n is zero, 1 or 2; and pharmaceutically acceptable salts thereof. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migaine, emesis or postherpetic neuralgia.Type: ApplicationFiled: March 4, 2004Publication date: December 16, 2004Inventors: Jose Luis Castro Pineiro, Duncan Shaw, Brian Williams
-
Patent number: 6756372Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds.Type: GrantFiled: November 2, 2001Date of Patent: June 29, 2004Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Michel Jose Emmanuel, Weimin Liu, Denice Mary Spero, Sanxing Sun, David S. Thomson, Yancey David Ward
-
Patent number: 6743788Abstract: Disclosed are novel aromatic compounds of the formula(I) described herein, wherein G, E, W, Ar, X, Y and Z are disclosed herein. The compounds are useful for treating cytokine mediated diseases or conditions such as chronic inflammatory diseases. Also disclosed are pharmaceutical compositions containing and processes of making such compounds.Type: GrantFiled: May 17, 2002Date of Patent: June 1, 2004Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Pier Francesco Cirillo, Victor Kamhi, John Robinson Regan, Michele Tsang
-
Publication number: 20040053921Abstract: Disclosed are cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (Ia) and (Ib) where R2, R3, R4, R6, R8 and Y are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.Type: ApplicationFiled: October 24, 2002Publication date: March 18, 2004Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Younes Bekkali, Denice Mary Spero, Sanxing Sun, Yancey David Ward
-
Publication number: 20040006227Abstract: The invention relates to polycyclic aryl and heteroaryl substituted 4-pyrone compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.Type: ApplicationFiled: January 31, 2003Publication date: January 8, 2004Inventors: Michael S. South, Chun C Ma, Kevin J Koeller, Hayat K Rahman, William L Neumann
-
Publication number: 20040002492Abstract: The application concerns a compound of formula I: 1Type: ApplicationFiled: February 24, 2003Publication date: January 1, 2004Applicant: Kudos Pharmaceuticals LtdInventors: Graeme Cameron Murray Smith, Niall Morrison Barr Martin, Stephen Philip Jackson, Mark James O'Connor, Alan Yin Kai Lau, Xiao-Ling Fan Cockcroft, Ian Timothy Williams Matthews, Keith Allan Menear, Laurent Jean Martin Rigoreau, Marc Geoffery Hummersone, Roger John Griffin
-
Publication number: 20030186976Abstract: There is provided benzofuryl-&agr;-pyrone derivative represented by the following structural formula (I): 1Type: ApplicationFiled: May 12, 2003Publication date: October 2, 2003Applicant: TEIJIN LIMITED, MICROBIAL CHEMISTRY RESEARCH FOUNDATIONInventors: Yoshimitsu Naniwa, Hiroshi Imai, Tomohide Ida, Emiko Muratani, Kazuo Kitai, Yoshinori Sugimoto, Tomomi Kosugi, Akiko Takeuchi, Kunihito Watanabe, Takami Tomiyama, Tomio Takeuchi, Masa Hamada
-
Publication number: 20030186962Abstract: of the formula (IV): 1Type: ApplicationFiled: November 16, 2001Publication date: October 2, 2003Inventors: Martin Quibell, Steven Taylor, Urszula Grabowska, Magnus Nilsson, Veronique Morrison
-
Patent number: 6586428Abstract: The present invention relates to combined preparations comprising a morpholinyl anthracycline administered in combination anticancer agents chosen from an alkylating agent, an antimetabolite, a topoisomerase II inihbitor, a topoisomerase I inhibitor, an antimitotic drug and a platinum derivative, which are useful anticancer therapy, particularly in the treatment of a primary or metastatic liver cancer.Type: GrantFiled: October 31, 2002Date of Patent: July 1, 2003Assignee: Pharmacia Italia, S.p.A.Inventors: Maria Cristina Geroni, Marina Ripamonti, Michele Caruso, Antonino Suarato
-
Patent number: 6537990Abstract: The present invention relates to combined preparations comprising a morpholinyl anthracycline administered in combination anticancer agents chosen from an alkylating agent, an antimetabolite, a topoisomerase II inhibitor, a topoisomerase I inhibitor, an antimitotic drug and a platinum derivative, which are useful anticancer therapy, particularly in the treatment of a primary or metastatic liver cancer.Type: GrantFiled: October 25, 2001Date of Patent: March 25, 2003Assignee: Pharmacia Italia S.p.A.Inventors: Maria Cristina Geroni, Marina Ripamonti, Michele Caruso, Antonino Suarato
-
Patent number: 6458830Abstract: The present invention relates to compounds of the formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and n are defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis and postherpetic neuralgia.Type: GrantFiled: September 10, 2001Date of Patent: October 1, 2002Assignee: Merck Sharp & Dohme Ltd.Inventors: Simon Neil Owen, Eileen Mary Seward, Christopher John Swain, Brian John Williams
-
Patent number: 6316505Abstract: Block copolymers containing a fluorinated hydrocarbon unit, a hydrocarbon unit, and a poly(oxyethylene) unit are useful in fluid formulations of pharmaceutical agents. A typical embodiment is: C11H23—CONHC2H4NHCO—C8F16—CONHC2H4NHCOO—(C2H4O)34—H.Type: GrantFiled: August 5, 1999Date of Patent: November 13, 2001Assignee: Supratek Pharma, Inc.Inventors: Alexander V. Kabanov, Serguei V. Vinogradov
-
Patent number: 6265446Abstract: Hydrazine derivatives of the formula wherein R1 represents lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl, aryl or aryl-lower alkyl, R2 represents heterocyclyl or NR5R6, R3 represents hydrogen, lower alkyl, halo-lower alkyl, cyano-lower alkyl, hydroxy-lower alkyl, amino-lower alkyl, lower alkoxy-lower alkyl, lower alkoxycarbonyl-lower alkyl, lower cycloalkyl-lower alkyl, aryl-lower alkyl, heterocyclyl-lower alkyl, heterocyclylcarbonyl-lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, aryl, heteroaryl or aryl-lower alkyl, R4 represents lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl or a grouping of the formula -Z-aryl, -Z-heterocyclyl or —(CH2)n—, CH═CR7R8, R5 and R6 each independently represent hydrogen or lower alkyl, R7 and R8 each independently represent hydrogen or lower alkyl or R7 and R8 together represent lower alkylene in which one CH2 group is optionally replaced by a hetero atom, X and Z each represType: GrantFiled: November 22, 1999Date of Patent: July 24, 2001Assignee: Hoffmann-La Roche Inc..Inventors: Michael John Broadhurst, William Henry Johnson, Daryl Simon Walter
-
Patent number: 6117870Abstract: A cyclic amide derivative of formula (I): ##STR1## wherein R.sup.1 represents a substituted alkyl group, a substituted alkenyl group, a substituted amino group, a substituted alkoxyl group, a substituted alkylthio group, a substituted carbamoyl group, a substituted sulfonamide group or a substituted amide group; the ring A represents a saturated cyclic alkyl group with 5 to 7 carbon atoms or a hetero-atom-containing saturated heterocyclic group with 3 to 6 carbon atoms; R.sup.2 represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aromatic hydrocarbon group or a substituted or unsubstituted heterocyclic group; R.sup.3 represents a hydrogen atom, a group represented by the general formula R.sup.4 O-- or a group represented by the general formula R.sup.5 (R.sup.6)N-- wherein R.sup.Type: GrantFiled: November 10, 1999Date of Patent: September 12, 2000Assignee: Fujirebio Kabushiki KaishaInventors: Akihiko Hosoda, Nobuo Kobayashi, Naoko Tanabe, Tsuneo Koji, Masahiro Shibata, Akihiro Sekine, Masaharu Dozen
-
Patent number: 6113812Abstract: A photochromic article that includes a host material and a photochromic amount of a benzopyran compound, the benzopyran compound represented by one of the formulas: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, and R.sub.10 are selected from hydrogen, a stable organic radical, a heterocyclic group, halogen, a nitrogen-substituted group, and a nitrogen-substituted ring compound.Type: GrantFiled: August 4, 1997Date of Patent: September 5, 2000Assignee: Vision-Ease Lens, Inc.Inventor: Frank J. Hughes
-
Patent number: 6087359Abstract: A thioaryl sulfonamide hydroxamic acid compound that inter alia inhibits matrix metalloprotease activity is disclosed as are a treatment process that comprises administering a contemplated thioaryl sulfonamide hydroxamic acid compound in a MMP enzyme-inhibiting effective amount to a host having a condition associated with pathological matrix metalloprotease activity.Type: GrantFiled: September 10, 1999Date of Patent: July 11, 2000Inventors: Daniel P. Getman, Daniel P. Becker, Thomas E. Barta, Clara I. Villamil, Susan L. Hockerman, Louis J. Bedell, Hui Li, John N. Freskos, Robert M. Heintz, Joseph J. McDonald, Gary A. DeCrescenzo
-
Patent number: 6005103Abstract: The present invention relates to novel tri- and tetrasubstituted pyrones and related structures which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The pyrone derivatives are useful in the development of therapies for the treatment of bacterial and viral infections and diseases, including AIDS. The present invention is also directed to methods of synthesis of multifunctionalized pyrones and of related structures.Type: GrantFiled: October 12, 1994Date of Patent: December 21, 1999Assignee: Warner-Lambert CompanyInventors: John Michael Domagala, Elizabeth Lunney, Kimberly Suzanne Para, Josyula Venkata Nagendra Vara Prasad, Bradley Dean Tait
-
Patent number: 5969140Abstract: Naphthalene derivatives of the formula [I]: ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and are each H, protected or unprotected OH, one of R.sup.3 and R.sup.4 is protected or unprotected hydroxymethyl, and the other is H, lower alkyl, or protected or unprotected hydroxymethyl, R.sup.5 and R.sup.6 are the same or different and are each H, substituted or unsubstituted lower alkyl, substituted or unsubstituted phenyl or protected or unprotected NH.sub.2, or both combine together with the adjacent N to form substituted or unsubstituted heterocyclic group, and pharmaceutically acceptable salts thereof, these compounds showing excellent bronchoconstriction inhibitory activity, and hence, being useful in the prophylaxis or treatment of asthma.Type: GrantFiled: July 2, 1998Date of Patent: October 19, 1999Assignee: Tanabe Seiyaku Co., Ltd.Inventors: Tatsuzo Ukita, Katsuo Ikezawa, Shinsuke Yamagata
-
Patent number: 5914351Abstract: Compounds of the formula ##STR1## wherein Q is a hydrazone derivative;R.sup.1 is hydrogen, halogen, alkyl or alkoxy;R.sup.2 is hydrogen, halogen, alkyl, alkoxy, alkenoxy, alkynyloxy, halomethyl, trifluoromethoxy, alkylthio, nitro or cyano; andR.sup.6 is a substituted carboxamide, carbothioamide, phosphonosoamide, or phosphonothioamide,useful as anti-HIV agents.Type: GrantFiled: December 12, 1997Date of Patent: June 22, 1999Assignees: Uniroyal Chemical Company, Inc., Uniroyal Chemical Co./CIE.Inventors: Walter Gerhard Brouwer, Ewa Maria Osika
-
Patent number: 5869662Abstract: Benzopyran compounds represented by the formulas: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, and R.sub.10 are selected from hydrogen, a stable organic radical, a heterocyclic group, halogen, a nitrogen-substituted group, and a nitrogen-substituted ring compound.Type: GrantFiled: July 17, 1997Date of Patent: February 9, 1999Assignee: Vision-Ease Lens, Inc.Inventor: Frank J. Hughes
-
Patent number: 5808062Abstract: The present invention relates to novel tri- and tetrasubstituted pyrones and related structures which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The pyrone derivatives are useful in the development of therapies for the treatment of bacterial and viral infections and diseases, including AIDS. The present invention is also directed to methods of synthesis of multifunctionalized pyrones and of related structures.Type: GrantFiled: October 12, 1994Date of Patent: September 15, 1998Assignee: Warner-Lambert CompanyInventors: John Michael Domagala, Edmund Lee Ellsworth, Elizabeth Lunney, Daniel Fred Ortwine, Kimberly Suzanne Para, Josyula Venkata Nagendra Vara Prasad, Tomi Sawyer, Bradley Dean Tait
-
Patent number: 5795981Abstract: Squarylium compounds of the formula: ##STR1## (in which Q.sup.1 and Q.sup.2 are each a chromophoric group having an aromatic unsaturated system conjugated with the squarylium ring and such that in the compounds of formulae Q.sup.1 CH.sub.2 R.sup.1 and Q.sup.2 CH.sub.2 R.sup.2 the methylene hydrogens are active hydrogens, R.sup.1 and R.sup.2 are each independently a hydrogen atom or an aliphatic or cycloaliphatic group, and R.sup.3 and R.sup.4 are each independently a hydrogen atom, or an acyl, aliphatic, cycloaliphatic, aromatic or heterocyclic group, subject to the proviso that one of R.sup.3 and R.sup.4 may be an amino or substituted amino group, or one of R.sup.3 and R.sup.4 is a hydrogen atom and the other is an organosulfonyl group, or R.sup.3 and R.sup.4 together with the intervening nitrogen atom form a nitrogenous heterocyclic ring) are useful as near infra-red absorbers.Type: GrantFiled: December 16, 1996Date of Patent: August 18, 1998Assignee: Polaroid CorporationInventors: John W. Lee, Donald A. McGowan, Mark R. Mischke, Socorro M. Ramos, Stephen J. Telfer